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Hannu Alho1,2
Abstract
Background: Poor quality of sleep among alcoholics and persons undergoing alcohol withdrawal has been
described as a possible cause of alcohol relapse. It has been suggested earlier that nitrous oxide gas has a
significant effect on the signs of alcohol withdrawal syndrome (AWS) and thus might be expected to reduce sleep
disturbance during withdrawal. The aim of the present study was to investigate sleep quality during alcohol
withdrawal, to evaluate the correlation between sleep quality and the severity of AWS and alcohol craving, and to
determine if nitrous oxide treatment does counteract withdrawal’s effects on the quality of sleep. Voluntary
patients (n = 105) admitted to the A-Clinic detoxification center with AWS were included in the study. The AWS
patients were randomly assigned to one of the following 45-minute gas treatments: (1) nitrous oxide/oxygen;
(2) normal air/O2; and (3) medical (normal) air. The study was single-blind by design. Sleep quality was assessed
after these treatments during the inpatient period; sleep time, sleep efficiency and the fragmentation of sleep were
recorded by wrist-worn actigraphs. Severity of AWS was evaluated by the Clinical Institute Withdrawal Assessment
of Alcohol Scale (CIWA-Ar) and that of alcohol dependence and craving by the Obsessive Compulsive Drinking
Scale [OCDS] and the Severity of Alcohol Dependence Data (SADD) questionnaire.
Results: The fragmentation index and the time awake while in bed were both much above the reference values
for the Finnish population. These values reflect the restless and disturbed night sleep of the subjects. The only
statistically significant effects between the treatment groups were found in the correlations of CIWA-Ar (severity of
AWS) scores, OCDS-scores (alcohol craving) and coffee consumption, all of which were positively associated with
movement time and negatively with total sleep time and sleep efficiency. The sleep quality of patients treated
with nitrous oxide gas did not differ from the sleep quality of those treated with normal air.
Conclusions: The severity of AWS and coffee consumption had the most significant negative impact on sleep
quality. According to our results, nitrous oxide gas does not differ from placebo in its effect on sleep quality during
alcohol withdrawal.
Background
Alcohol dependence and sleep disorders are common
and often seen in combination. Chronic drinking
reduces sleep latency, diminishes sleep efficiency, and
disrupts the sleep pattern [1]. Withdrawal from alcohol
usually results in sleep disruption, especially during the
first week of withdrawal [2]. Most of the investigations
using polysomnographic methods (PSG) have shown
that alcohol withdrawal syndrome (AWS) is associated
with long sleep, frequent awakenings and reduced slow
wave sleep [3-5].
The alterations in sleep quality seen in association
with AWS can last for several months [6]. If, after a per-
iod of abstinence, sleep disturbances remain, the prob-
ability of relapse increases [7]. Clark and co-workers [8]
reported that subjects who relapsed had shortened rapid
eye movement (REM) sleep latency, increased percen-
tage of REM sleep and increased REM density. In the
later investigation the increased REM density was suc-
cessfully used as a predictor for relapse among alcoholic
subjects with a secondary diagnosis of depression [4].
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Sleep parameters can vary significantly between indivi-
duals. Sleep quality has commonly been assessed by
using PSG and a variety of subjective self-report ques-
tionnaires. An alternative approach to PSG is to study
sleep quality with wrist-worn accelometers, producing
records called “actigraphs”. Several studies have con-
firmed that actigraphy is a valid method for estimating
sleep when compared to PSG [9]. Actigraphy is a useful
method for investigating group differences and sleep
pattern variation over time, with many benefits over
PSG. The wrist-worn actigraph is a small device and
thus less disturbing than classical PSG equipment.
Accelometers can be used over long periods of time and
during everyday activities, unlike PSG, which is usually
recorded in a sleep laboratory over one or two nights.
Results from actigraphic recordings also correlate well
with measurements of melatonin and core body tem-
perature rhythms. Actigraphs allow acceptable monitor-
ing of the sleep-wake cycle, circadian rhythms and
quality of sleep, and they have been used in several
investigational areas [10-14], including alcohol research
[14].
The treatment of AWS has been traditionally based on
the application of a sedative medication such as benzo-
diazepine. Over a decade ago, it was suggested that
nitrous oxide gas is also effective in the treatment of
AWS [14-18], but this practice remains controversial.
Support for using nitrous oxide was based on uncon-
trolled trials, while our recent placebo-controlled trial
showed no differences in scores on the Clinical Institute
Withdrawal Assessment of Alcohol Scale (CIWA-Ar) or
in the use of benzodiazepines between subjects treated
with nitrous oxide and those administered a placebo
[19,20].
The mechanism of action of nitrous oxide is not
known, but it has been speculated that it could activate
melatonin release [21] through a direct interaction with
opioid receptors. Pharmacological application of melato-
nin has resulted in a sleep-inducing effect and improve-
ment in sleep quality [22]. Moreover melatonin levels in
subjects with AWS have been reported to be lower than
in controls [23]. If N2O could induce melatonin release,
a possible improvement in sleep quality would be
expected. Examining the effects of nitrous oxide on the
changes in sleep parameters provides another indepen-
dent means for determining whether the gas is capable
of reversing the effects of alcohol withdrawal. The pre-
sent investigation evaluates sleep quality during alcohol
withdrawal and its relation to various patient character-
istics. The effect of nitrous oxide on sleep quality
among subjects with AWS was also assessed. The pre-
sent study is a complement to the previous work of the
same team [19,20].
Methods
Subjects
Each patient who sought treatment for alcohol withdra-
wal symptoms at the A-Clinic detoxification center in
Leppävaara (Espoo, Finland) was interviewed. The first
105 voluntary inpatients (80 men and 25 women) meet-
ing the study criteria were included in the study. All the
participants gave informed consent. The study protocol
was approved by the Helsinki University Central Hospi-
tal Ethical Committee and the study was conducted
according to the International Conference on Harmoni-
zation’s Good Clinical Practice Guidelines and the
Declaration of Helsinki 1996. The National Agency for
Medicines of Finland was notified of the study.
The inclusion criteria were age between 18 and
60 years (mean age was 44 for males, and 43 for females),
and the presence of alcohol withdrawal symptoms. Exclu-
sion criteria were an alcohol breath concentration higher
than 1 μg/ml, a serious or unstable medical condition,
current psychiatric disorders, and current use of psycho-
tropic medications, previous N2O treatment, and recent
serious convulsions during alcohol withdrawal.
Study protocol
Subjects were randomly assigned to one of the following
45-minute gas treatments: (1) nitrous oxide/O2 (O2;
starting concentration 30%, maximum 70%, aiming at a
30% EtN2O concentration), (n = 35); (2) normal air/O2
(flow 50%/50%, final O2 concentration 70%), (n = 35);
and (3) normal air, (n = 35). The study was single-
blinded by design with the patients being unaware of
which treatment they were receiving. Further clinical
details for this sample and a description of the study
procedure are published elsewhere [19,20].
On admission, the patients completed the Severity of
Alcohol Dependence Data (SADD) questionnaire [24]
and the Obsessive-Compulsive Drinking Scale (OCDS)
[25] questionnaire. Directly after the treatment, the
ward nurse measured the CIWA-Ar scores. The mea-
surement was repeated at 2 hours, 4 hours, 6 hours,
16-18 hours, and 40-42 hours after treatment. When the
CIWA-Ar score was higher than 10, patients were admi-
nistered 10 mg diazepam (orally, in liquid form) every
second hour. Temazepam (20 mg/dose) was adminis-
tered at night when the patient claimed sleeplessness
(20 mg/night). No other medication was allowed during
the study period. Coffee consumption (cups/day) and
cigarette smoking (cigarettes/day) were assessed by a
daily query.
Sleep quality
During the inpatient period (1-3 days), physical activity,
sleep time, and sleep quality for each subject were
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recorded by a wrist-worn actigraph (Actiwatch Plus®,
Cambridge Neurotechnology Ltd, UK) device. The
resulting actigraphs provide information about the qual-
ity and amount of sleep and the activity of the subject,
as well as the intensity and duration of movements over
extended periods of time. Sleep-wake patterns are esti-
mated from periods of activity and inactivity based on
this movement. The subjects wore the actigraph on
their non-dominant wrist at all times, except when bath-
ing or swimming. The actigraphic data were analyzed
using one minute epochs with software provided by the
manufacturer (The Actiwatch Sleep Analysis software,
version 3.24, Cambridge Neurotechnology Ltd, UK).
A window between 10 pm and 6 am was used to com-
pute nocturnal sleep parameters. Subjects marked what
time they went to bed in the evening and woke up in the
morning by pressing the event marker of the actigraphs.
The period between these two events defined the time in
bed (TIB). In this study we used the following actigraphic
parameters to estimate the amount and quality of sleep:
total sleep time (the length of sleep as determined by the
Actiwatch algorithm), time awake during night (between
10 pm and 6 am), percentage of time awake during night,
sleep efficiency (the percentage of time spent asleep
while in bed), number of minutes moving (total number
of minutes moving during sleep time) and fragmentation
index. The fragmentation index is an indicator of the
restlessness of sleep. It is the sum of moving time during
nighttime as a percentage compared to the percentage of
immobile periods. We used a medium sensitivity thresh-
old of accelerations of 0.05 g with one minute epochs in
the data storage and analyses of the Actiwatch signal.
There are no official normal values for the fragmentation
index (FRI). Based on our clinical experience of several
hundred actigraphic recordings in subjects affected by
insomnia, other sleep disorders, and in healthy people,
we defined a limit of 30 for good sleep and 40 for the
upper normal fragmentation index. Among working Fin-
nish adults, less than 50% have a FRI>30 and less than
18% have a FRI>40. The time awake during the night, as
measured by actigraphy, in healthy Finnish subjects has
been found to be lower than 20 minutes [12], which is in
accordance with other studies [26,27].
Statistics
All statistical analyses were performed using SPSS ver-
sion 11.5 statistical package (SPSS Inc, Chicago, IL). Dif-
ferences in the sleeping variables were analyzed using
the non-parametric Kruskal-Wallis one-way analysis of
variance. When the Kruskal-Wallis test indicated the
presence of statistically significant differences between
the treatments at p < 0.05, the differences were tested
using post hoc pair-wise multiple comparisons. To test
for significant differences between the treatment arms in
the sleeping variables, a general linear model (repeated
measures) analysis and post hoc pair-wise multiple com-
parisons of the SPSS-package were used. In all multiple
comparisons tests, the p values were adjusted using the
Bonferroni method. Associations between sleep variables
and explanatory variables were assessed by a forward
stepwise multiple regression analysis (homoscedasticity).
The following variables were included in the model:
gender, age, breath alcohol concentration before treat-
ment, total use of diazepam (mg), total use of temaze-
pam [mg], coffee consumption (one unit is one coffee
cup), CIWA-Ar, SADD, and OCDS before treatment,
after 2 hours beyond the end of treatment, after 6 hours
[evening one], after 16-18 hours (evening two), after
40-42 hours (evening three).
Results
Table 1 summarizes the median values for all sleep vari-
ables studied for the three treatments. The significance
levels did not change when the use of diazepam and
temazepam were included as covariates in the analysis.
Table 2 shows gender and age ratios and baseline coffee
consumption inside the groups (the numbers presented
refer to the numbers of subjects). All groups spent more
than 20 minutes awake on each of the nights (Figure 1).
The sleep was disrupted, which was seen also in the
high fragmentation indices (Figure 2).
Treatment differences
As shown in Table 1, the percentage of time awake in
the nitrous oxide group increased significantly from the
first night to the second (p < 0.001); a similar trend is
seen in the time awake measure, though it failed to
reach significance. There were no other significant
changes within groups on different nights and also none
between groups on the same nights.
Coffee consumption
The results of the forward stepwise multiple regression
analysis showed that in all groups during night 2 the
sleep quality was significantly affected by coffee con-
sumption: it was positively associated with the total
minutes awake time (r2 = 0.271; p = 0.016), the percen-
tage of time awake during night time (r2 = 0.263; p =
0.017), and the movement time [r2 = 0.226; p = 0.029],
and negatively associated with the total sleep time (r2 =
0.223; p = 0.031) and the sleep efficiency (r2 = 0.223;
p = 0.030).
Among subjects treated with nitrous oxide, coffee con-
sumption was negatively associated with sleep efficiency
(r2 = 0.210; p = 0.025) and with total sleep time (r2 =
0.209; p = 0.025) during night 1 also.
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CIWA-Ar
The CIWA-Ar scores on night 1 in the group treated
with treatment 2 (normal air/O2) were negatively asso-
ciated with the total sleep time (r2 = 0.408; p = 0.001)
and with the sleep efficiency (r2 = 0.409; p = 0.001); on
night 2, CIWA-Ar scores were positively associated with
total minutes awake during sleep time r2 = 0.318; p =
0.005), % time awake during night-time (r2 = 0.341; p =
0.003), movement time (r2 = 0.273; p = 0.01) and frag-
mentation index (r2 = 0.321; p = 0.005). In the nitrous
oxide group, no significant association was observed.
OCDS and SADD
Among subjects treated with normal air, sleep quality on
night 3 correlated with OCDS and SADD scores. High
OCDS scores were positively associated with total time
awake (r2 = 0.269; p = 0.011), % of time awake during
night (r2 = 0.327; p = 0.004), and movement time (r2 =
0.396; p = 0.001), and were negatively associated with
Table 2 Gender, age and coffee consumption in three
treatment groups
Nitrous oxide Oxygen Air Total
Gender
Male 25 21 23 69
Female 7 9 7 23
Age
27-36 6 3 8 17
37-46 14 13 12 39
47-56 10 12 10 32
56 + 2 2 0 4
Coffee consumption
0 cups/day 9 9 3 21
1-2 cups/day 20 19 21 60
3-5 cups/day 1 2 3 6
Table 1 Median values [± semi-interquratile ranges] for sleep parameters on three nights of alcohol withdrawal for
three treatment groups (the last block shows the number of subjects providing data in each condition)
Variable night Nitrous oxide Oxygen Air
n 1 32 30 30
2 32 28 30
3 31 25 30
Total sleeping time [h] 1 6.9 ± 0.7 6.8 ± 0.3 7.1 ± 0.5
2 6.6 ± 0.5 6.8 ± 0.5 6.6 ± 0.7
3 6.6 ± 0.5 6.8 ± 0.5 6.8 ± 0.5
Time awake [min] 1 46.0 ± 35.6 55.5 ± 13.4 47.5 ± 14.4
2 66.0 ± 22.1 52.5 ± 31.3 53.0 ± 21.5
3 55.0 ± 26.3 50.0 ± 25.5 48.0 ± 15.8
% of time awake 1 10.3 ± 7.7 12.3 ± 3.2 9.9 ± 3.2
2 15.0 ± 4.8** 11.2 ± 6.5 11.7 ± 4.5
3 11.6 ± 5.7 11.0 ± 5.3 10.4 ± 3.7
Sleep efficiency 1 86.3 ± 8.3 85.6 ± 3.8 88.3 ± 6.4
2 82.6 ± 6.9 84.8 ± 6.8 82.6 ± 8.1
3 82.9 ± 6.6 85.0 ± 6.5 84.9 ± 6.9
Movement time [min] 1 7.2 ± 4.4 9.0 ± 3.2 7.5 ± 2.6
2 9.1 ± 3.8 8.2 ± 4.5 10.6 ± 4.9
3 8.5 ± 4.3 8.9 ± 4.1 7.4 ± 2.5
Fragmentation index 1 44.5 ± 19.1 50.5 ± 13.8 46.0 ± 13.2
2 51.7 ± 12.4 49.0 ± 13.7 50.8 ± 16.2
3 49.5 ± 16.2 45.4 ± 9.1 37.1 ± 12.5
** Significantly different from night 1, p < 0.001.
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Figure 1 Median values for the time awake per night in the three
treatment groups during alcohol withdrawal and the normal
reference value. There were no significant differences between the
groups, but all data points were far above the reference level.
Lahti et al. BMC Research Notes 2011, 4:108
http://www.biomedcentral.com/1756-0500/4/108
Page 4 of 7
total sleep time (r2 = 0.260; p = 0.013) and sleep effi-
ciency (r2 = 0.261; p = 0.013). SADD was positively
associated with the fragmentation index (r2 = 0.260; p =
0.013). In the other groups no significant associations
were observed.
Discussion
Although sleep parameters can vary between indivi-
duals, there are relatively consistent normal values: in a
healthy population, subjects tend to sleep between 6
and 9 hours per night, with sleep efficiency around 85%
[28]. In our study with a population of alcoholics with
alcohol withdrawal symptoms, both total sleep time and
sleep efficiency in all treatment groups were close to
values that are considered normal for healthy subjects.
This may be due to the usage of benzodiazepines for
AWS; the total usage of benzodiazepines (diazepam +
temazepam) during the nights was 32.2 (nitrous oxygen
group), 35.7 (oxygen group) and 27.7 (air group) mg.
The differences between the treatment groups are not
statistically significant [20]. Both the fragmentation
index and the time awake during the night were, how-
ever, much higher than the usual values that we have
found in a database of several hundred actigraphic
recordings made among subjects affected by insomnia
and among healthy people in Finland. In our sleep
clinic population we consider a fragmentation index
value below 30 as an indicator of normal good sleep,
and a value above 40 as abnormally high (Partinen et al.
unpublished results). For the time awake during the
night, values higher than 20 minutes are usually found
in patients with sleep maintenance insomnia [13,26].
The median fragmentation index for our groups ranged
from 35.75 to 52.70 and the time awake from 38 to 66
minutes; these high values reflect a restless and dis-
turbed night sleep for the subjects. In summary, our
results indicating poor sleep quality among subjects
with AWS are in agreement with several investigations
that have shown that abstinence from alcohol initially
induces a degradation of sleep quality, characterized by
lighter sleep, less deep sleep, and more awakenings
[5,14].
High CIWA-Ar scores have been found to be nega-
tively associated with total time awake, and positively
with fragmentation index and movement time [29].
Concordantly, our multivariate analysis shows that the
severity of AWS (assessed by CIWA-Ar scores) and cof-
fee consumption are the parameters with the most sig-
nificant negative impacts on sleep quality. The severity
of alcohol dependence (estimated by the SADD scale)
and the craving for alcohol (estimated by the Obsessive-
Compulsive Drinking Scale, OCDS) also correlate nega-
tively with sleep quality.
We found no significant differences in sleep quality
between patients treated with either nitrous oxide or
placebo. More specifically, there was no indication that
nitrous oxide counteracted the sleep disruption during
alcohol withdrawal. As shown in Figure 1, all three
groups were awake more than normal on all three
nights of withdrawal, and for two of the three nights,
the nitrous oxide group had the largest increase. Simi-
larly, the fragmentation index was elevated in all three
groups with no tendency for nitrous oxide to reduce the
disturbance (Figure 2). Rather, while the fragmentation
index of the control group appears to be approaching
the normal range by the third night of withdrawal, that
of the nitrous oxide group is still highly elevated. This is
in agreement with a previous analysis of the same sam-
ple [19] in which we found that N2O treatment pro-
duced signs of arousal instead of sedation.
The gold standard for sleep recording is a full-night
PSG recording. Actigraphy is an appropriate method to
estimate the sleep-wake cycle on an ambulatory basis
[27,30,31]. However, there are some limitations to using
actigraphy. First of all, without documenting the sleep-
and wake times with sleep diaries, actigraphy may over-
estimate the sleep time. It seems that the method does
not always accurately differentiate the periods of quiet
wakefulness and sleep [28,30]. Thus it is important to
always use sleep diaries in conjunction with actigraphy,
as we did here. Second, actigraphy seems to be useful
for measuring the rest-activity cycles of healthy indivi-
duals but it has to be pointed out that it is not clear
whether the accuracy of the method is lower when used
in clinical studies [9,27]. Thus our results may underes-
timate the degree of sleep disturbance in AWS. This
study was designed to compare sleep between different
treatment groups in AWS.
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Figure 2 Median sleep fragmentation indexes during three
alcohol withdrawal nights for the three treatment groups and
the normal reference value. There were no significant differences
between the groups.
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Conclusions
In conclusion, the results of the present investigation
demonstrate that subjects with AWS have a significantly
deteriorated sleep quality. In an actigraphic recording
this is characterized by high values for the fragmenta-
tion index and movement time, more awakenings, and
low sleep efficiency. Sleep quality did not differ signifi-
cantly between the three gas treatment groups. The pre-
sent results complement our previous studies with the
same sample [19,20], which demonstrated, using other
parameters, that nitrous oxide treatment is not more
effective than placebo in the treatment of AWS.
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